LMRI shares up after insider buy; Wall Street cut trims gains
Lumexa Imaging closed at $8.18 Thursday, up 10.5%, and traded at $8.53 after hours following news that director Brett Brodnax bought 35,000 shares at $7.25 each. Barclays cut its price target to $9 from $15, citing stronger growth at rival RadNet. Lumexa’s shares remain below their $18.50 IPO price from December. The company reaffirmed its 2026 revenue and earnings outlook.